icon-    folder.gif   Conference Reports for NATAP  
  IAS 2015: 8th IAS Conference on
HIV Pathogenesis Treatment and Prevention
Vancouver, Canada
18-22 July 2015
Back grey_arrow_rt.gif
The risk of cardiovascular disease and death over 10 years in HIV/HCV co-infected patients with and without steatosis ....mortality was high .....high rates of cardiovascular disease
  Reported by Jules Levin
IAS 2015 Vancouver July 19-23
C. Down, N. Mehta, K. Marks
NY Cornel Hosp
from Jules: in this patient group at Cornel/NY avg age 45 (30-63) 55% (59/106) had steatosis (fatty liver) fairly common was - alcohol use history, dislipidemia, diabetes, hypertension, overweight -
".....mortality for this population was very high.....The overall survival in this HIV/HCV co-infected cohort studied was strikingly low (25% mortality) given age and demographics at time of enrollment......Low survival rate and association between liver disease markers and survival in this cohort underscore importance of HCV treatment in HIV/HCV-coinfected individuals
........10-year CVD risk estimated by the Framingham Risk Score was 9.6%......data trended towards an increased rate of cardiovascular events, diabetes and decreased survival in patients with steatosis
Analysis of clinical outcomes showed non-significant trends towards DM (22%), decompensated liver disease (19%), MI (5%), CAD (5%), and PVD (5%) in the steatosis group compared to those without steatosis (11%, 15%, 2%, 4%, 4%, respectively) over the 10 year period...... Survival analysis was performed which showed a trend towards decreased survival in the steatosis group at the 5-year and 10-year timepoints with 5-year survival 88% and 10-year survival 65% in the steatosis group vs 93% and 73% at respective time points in the nonsteatosis group.